Home › Calculator › EDIT Dividend Calculator 2026
EDIT Dividend DRIP Calculator 2026
63.29% YieldHealthcareEditas Medicine, Inc. · NASDAQ
Price: $3.16 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When EDIT pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your EDIT snowball 📈
$10,000 in EDIT → $13119299412.84M in 10 years · $1,091,590,660,792,976.50/month
About Editas Medicine, Inc. (EDIT) — Dividend Analysis 2026
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Compare EDIT with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full EDIT DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open EDIT position with:
🌍 EDIT Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold EDIT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 63.29% | 60.49% | $6,329 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 53.80% | 51.00% | $5,380 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 50.63% | 47.83% | $5,063 / yr |
| 🇬🇧 UK ISA | 0% | 63.29% | 60.49% | $6,329 / yr |
| 🇬🇧 UK Taxable | 8.75% | 57.75% | 54.95% | $5,775 / yr |
| 🇨🇦 TFSA | 0% | 63.29% | 60.49% | $6,329 / yr |
| 🇨🇦 CA Taxable | 25% | 47.47% | 44.67% | $4,747 / yr |
| 🇦🇺 Super (pension) | 15% | 53.80% | 51.00% | $5,380 / yr |
| 🇦🇺 AU Taxable | 30% | 44.30% | 41.50% | $4,430 / yr |
| 🇩🇪 DE Taxable | 26.375% | 46.60% | 43.80% | $4,660 / yr |
| 🇫🇷 FR Taxable | 30% | 44.30% | 41.50% | $4,430 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 EDIT Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 EDIT Dividend Payment Schedule
EDIT pays quarterly — 4 times per year. Next ex-div: TBD.
📊 EDIT vs Healthcare Benchmarks
How EDIT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for EDIT sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ EDIT Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-17 | 51,700 | $2.55 | $131.8K | ||
| A-Award | 2026-06-17 | 51,700 | $2.55 | $131.8K | ||
| A-Award | 2026-06-17 | 51,700 | $2.55 | $131.8K | ||
| A-Award | 2026-06-17 | 51,700 | $2.55 | $131.8K | ||
| A-Award | 2026-06-17 | 51,700 | $2.55 | $131.8K | ||
| Sale | 2026-06-03 | 464 | $2.70 | $1.3K | ||
| Sale | 2026-06-03 | 15,380 | $2.70 | $41.5K | ||
| Sale | 2026-06-03 | 731 | $2.70 | $2.0K | ||
| A-Award | 2026-03-12 | 1,015,200 | $2.54 | $2.58M | ||
| A-Award | 2026-03-12 | 292,856 | $2.54 | $743.9K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the EDIT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Editas Medicine, Inc. (EDIT) is currently trading at $3.16, 96% below its 52-week high. The current dividend yield is 63.29% based on an annual payout of $2.00 per share.
EDIT (Editas Medicine, Inc.) — 63.29% Dividend Yield Analysis
Editas Medicine, Inc. (EDIT) is a healthcare stock currently trading at $3.16 with a dividend yield of 63.29%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (63.29%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.